Inhibrx, Inc. (INBX) 

Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcinoma; INBRX-105, a tetravalent conditional agonist of programmed death-ligand 1 and a conditional agonist of 4-1BB that is in Phase 1 clinical trials to treat patients with locally advanced or metastatic solid tumors; and INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also provides INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company was founded in 2010 and is headquartered in La Jolla, California.

Show less

Over the last 12 months, insiders at Inhibrx, Inc. have bought $9.9M and sold $10.29M worth of Inhibrx, Inc. stock.

On average, over the past 5 years, insiders at Inhibrx, Inc. have bought $18.62M and sold $6.72M worth of stock each year.

Highest buying activity among insiders over the last 12 months: VIKING GLOBAL INVESTORS LP (10 percent owner) — $108.9M.

The last purchase of 511,627 shares for transaction amount of $9.9M was made by VIKING GLOBAL INVESTORS LP (10 percent owner) on 2023‑08‑28.